Cytek Biosciences, Inc.
CTKB
Positions held
Your positionsCTKB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $696.71M | Enterprise value | $461.17M | Trailing P/E | — | Forward P/E | 76.57 |
| PEG | — | Price / book | 2.16 | Beta | 1.16 | Dividend yield | 0.00% |
| Revenue growth | 5.6% | Earnings growth | — | Gross margin | 51.9% | Operating margin | -29.5% |
| Profit margin | -39.0% | ROE | -23.0% | ROA | -6.3% | Debt / equity | 0.08 |
| Current ratio | 4.48 | Free cash flow | $9.30M | Analyst recommendation | none | Mean target | $5.56 |
| 52w high | $6.21 | 52w low | $3.31 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $48.1M | $44.1M | $62.1M | $52.3M | $45.6M |
| Op margin | -23.7% | -41.8% | -9.0% | -17.6% | -23.3% |
| Net income | -$12.2M | -$18.9M | -$44.1M | -$5.5M | -$5.6M |
| Gross margin | 58.9% | 48.2% | 52.9% | 52.7% | 52.3% |
| Gross profit | $28.3M | $21.3M | $32.9M | $27.6M | $23.9M |
| Operating income | -$11.4M | -$18.5M | -$5.6M | -$9.2M | -$10.6M |
- Revenue +9% vs prior quarter ($48M vs $44M).
- Gross margin 58.9% (was 48.2% prior quarter).
- Operating margin expanded to -23.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $201M | $200M | $193M | $164M | — |
| Op margin | -20.0% | -10.2% | -14.4% | -1.1% | — |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.6M | — |
| Gross margin | 51.8% | 55.4% | 56.7% | 61.6% | — |
| Gross profit | $104M | $111M | $109M | $101M | — |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Fund Divests Cytek Biosciences (CTKB) Following Revenue Slowdown and Declining Profitability
2026-09-23 · Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
2026-09-17 · Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
2026-09-09 · Cytek Biosciences, Sysmex Europe Collaborate to Deliver Clinical Flow Cytometry Workflows
2026-09-09 · Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
2026-09-09 · Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing
2026-09-03 · Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS
2026-09-01 · Cytek Biosciences to Participate in Upcoming Investor Conferences
2026-08-21 · Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
2026-08-12 · Cytek (CTKB) Q2 2026 Earnings Call Transcript
2026-08-06 · Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-08-06 · Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Price (daily)
Full chart · RSI · MACD · patterns